The results of a randomized clinical trial funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in children with type 2 diabetes show that children and adolescents treated with a combination of metformin and Avandia (rosiglitazone) had better glycemic control than children treated with metformin alone...

The FDA has issued a complete response letter to Japanese drug-maker Takeda Pharmaceutical regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone. Recently, Takeda provided postmarketing data from outside the U.S., and has been in discussion with the FDA. The FDA has requested...

Randy Jackson, Grammy Award-winning music producer and American Idol judge, who was diagnosed with type 2 diabetes in 2003, has partnered with Merck to help and encourage those with type 2 diabetes to live healthier lives. In a program called Taking Diabetes to Heart, Randy Jackson is using his personal experience to help others...

Studies have shown that excess insulin circulating in the bloodstream is a major independent risk factor for cardiovascular disease. However, a new study from Joslin Diabetes Center finds that this condition, called hyperinsulinemia,  itself does not cause hardening of the arteries, also known as atherosclerosis.   Scientists have...

Men with type 2 diabetes who are treated with insulin are at higher risk risk for major cardiovascular events (e.g., death, heart attack, stroke) according to a new study conducted by researchers at Brigham and Women’s Hospital (BWH). The researchers found that men with type 2 diabetes treated with insulin without a history of cardiovascular...

The European Commission has granted marketing authorization to Byetta (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos® (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. The EU approval was given...

A new study evaluating the efficacy and safety of adding dapagliflozin therapy to the treatment of type 2 diabetes patients whose blood glucose levels remain poorly controlled despite high doses of insulin was published today in the Annuls of Internal Medicine. The 24 week study conducted on 808 type 2 diabetes patients with...

Eli Lilly and Boehringer Ingelheim have announced Jentadueto tablets are now available by prescription in pharmacies across the U.S. Jentadueto is a new prescription medication for type 2 diabetes patients who need to control their blood sugar.  Jentadueto is a  twice daily medication combining two diabetes medicines — the dipeptidyl...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in the European Union (EU) for the expanded use of Byetta (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos® (pioglitazone), for the treatment of type 2...

The newly approved type 2 diabetes drug  Bydureon, made by Amylin Pharmaceuticals and Alkermes plc, is now available by prescription in U.S. pharmacies. Bydureon is the first and only once-weekly treatment for type 2 diabetes.  It was approved by the US FDA on January 27th 2012 as an adjunct to diet and exercise to improve glycemic...